Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/12575
Full metadata record
DC FieldValueLanguage
dc.contributor.authorPietrzak, Robert H-
dc.contributor.authorLim, Yen Ying-
dc.contributor.authorAmes, David-
dc.contributor.authorHarrington, Karra-
dc.contributor.authorRestrepo, Carolina-
dc.contributor.authorMartins, Ralph N-
dc.contributor.authorRembach, Alan-
dc.contributor.authorLaws, Simon M-
dc.contributor.authorMasters, Colin L-
dc.contributor.authorVillemagne, Victor L-
dc.contributor.authorRowe, Christopher C-
dc.contributor.authorMaruff, Paul-
dc.date.accessioned2015-05-16T02:17:28Z
dc.date.available2015-05-16T02:17:28Z
dc.date.issued2014-12-20-
dc.identifier.citationNeurobiology of Aging 2014; 36(3): 1231-8en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/12575en
dc.description.abstractMemory changes in preclinical Alzheimer's disease (AD) are often characterized by heterogenous trajectories. However, data regarding the nature and determinants of predominant trajectories of memory changes in preclinical AD are lacking. We analyzed data from 333 cognitively healthy older adults who participated in a multicenter prospective cohort study with baseline and 18-, 36-, and 54-month follow-up assessments. Latent growth mixture modeling revealed 3 predominant trajectories of memory change: a below average, subtly declining memory trajectory (30.9%); a below average, rapidly declining memory trajectory (3.6%); and an above average, stable memory trajectory (65.5%). Compared with the stable memory trajectory, high Αβ (relative risk ratio [RRR] = 2.1), and lower Mini-Mental State Examination (RRR = 0.6) and full-scale IQ (RRR = 0.9) scores were independently associated with the subtly declining memory trajectory; and high Αβ (RRR = 8.3), APOE ε4 carriage (RRR = 6.1), and greater subjective memory impairment (RRR = 1.2) were independently associated with the rapidly declining memory trajectory. Compared with the subtly declining memory trajectory group, APOE ε4 carriage (RRR = 8.4), and subjective memory complaints (RRR = 1.2) were associated with a rapidly declining memory trajectory. These results suggest that the preclinical phase of AD may be characterized by 2 predominant trajectories of memory decline that have common (e.g., high Αβ) and unique (e.g., APOE ε4 genotype) determinants.en
dc.language.isoenen
dc.subject.otherAPOEen
dc.subject.otherAlzheimer's diseaseen
dc.subject.otheren
dc.subject.otherMemoryen
dc.subject.otherTrajectoriesen
dc.titleTrajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeurobiology of agingen
dc.identifier.affiliationCentre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australiaen
dc.identifier.affiliationCogstate Ltd, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Nedlands, Western Australia, Australiaen
dc.identifier.affiliationDepartment of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USAen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australiaen
dc.identifier.affiliationNational Ageing Research Institute, Parkville, Victoria, Australiaen
dc.identifier.affiliationDepartment of Psychiatry, Yale School of Medicine, New Haven, CT, USAen
dc.identifier.affiliationUnited States Department of Veterans Affairs, National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven, CT, USAen
dc.identifier.affiliationAcademic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, The University of Melbourne, Kew, Victoria, Australiaen
dc.identifier.affiliationDepartment of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1016/j.neurobiolaging.2014.12.015en
dc.description.pages1231-8en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/25585532en
dc.contributor.corpauthorAustralian Imaging, Biomarkers and Lifestyle (AIBL) Research Groupen
dc.type.contentTexten
dc.type.austinJournal Articleen
local.name.researcherMasters, Colin L
item.languageiso639-1en-
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptMolecular Imaging and Therapy-
crisitem.author.deptMolecular Imaging and Therapy-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

44
checked on Nov 7, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.